Informed Investing
Subscribe
NewsArticlesLearnPodcastSubscribe

#Eli Lilly

NewsArticlesLearnPodcast
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? | The Motley Fool
OCTOBER 5, 2026

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? | The Motley Fool

In the healthcare investment landscape for 2026, Johnson & Johnson (JNJ) offers stability with a diversified portfolio and strong operational efficiency, reporting $94 billion in revenue and a net income of $27 billion. Conversely, Eli Lilly (LLY) showcases rapid growth, achieving $65.2 billion in revenue, driven by blockbuster...

Read More >
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years
JULY 9, 2026

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

The healthcare sector remains a top choice for dividend stocks, with AbbVie (ABBV) emerging as a standout for income-seeking investors. AbbVie boasts a forward dividend yield of 2.65%, supported by robust revenue growth from its diverse drug portfolio, including Skyrizi and Rinvoq. Recent acquisitions, like Apogee Therapeutics,...

Read More >
Informed Investing
About UsContact
PrivacyTermsCopyright

Informed Investing is for informational and educational purposes only and is not financial, investment, tax, or legal advice. Nothing on this site constitutes a recommendation, solicitation, or offer to buy or sell any security or financial product. Investing involves risk, including loss of principal. Content may be developed with the assistance of analytical and automated tools, including AI systems, and is subject to human editorial review. Information may be incomplete, inaccurate, or outdated. You should independently verify information before acting on it and consult a qualified professional as appropriate.

© 2026 Informed Investing. All rights reserved.